

David L Porter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9738450/publications.pdf>

Version: 2024-02-01

85
papers

18,627
citations

94381

37
h-index

62565

80
g-index

86
all docs

86
docs citations

86
times ranked

16146
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2011, 365, 725-733.	13.9	3,067
2	Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2013, 368, 1509-1518.	13.9	3,021
3	Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> , 2014, 124, 188-195.	0.6	2,080
4	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <i>Science Translational Medicine</i> , 2015, 7, 303ra139.	5.8	1,402
5	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2017, 377, 2545-2554.	13.9	1,390
6	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018, 24, 563-571.	15.2	1,150
7	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2016, 6, 664-679.	7.7	811
8	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , 2018, 558, 307-312.	13.7	574
9	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
10	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2017, 35, 1154-1161.	0.8	495
11	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , 2016, 127, 1117-1127.	0.6	381
12	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. <i>Nature</i> , 2022, 602, 503-509.	13.7	369
13	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. <i>Blood</i> , 2017, 130, 2317-2325.	0.6	273
14	A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. <i>Blood</i> , 2006, 107, 1325-1331.	0.6	209
15	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (SMT CTN 1203). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	2.2	200
16	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
17	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 415-422.	0.8	162
18	Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 567-572.	0.9	158

#	ARTICLE	IF	CITATIONS
19	Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With Malignancies. <i>Journal of Clinical Oncology</i> , 1999, 17, 1234-1234.	0.8	124
20	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. <i>Blood</i> , 2019, 134, 44-58.	0.6	118
21	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 556-556.	0.6	106
22	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2862-2871.	0.8	102
23	Chimeric Antigen Receptor Therapy for B-cell Malignancies. <i>Journal of Cancer</i> , 2011, 2, 331-332.	1.2	88
24	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	1.3	86
25	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
26	Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. <i>British Journal of Haematology</i> , 2015, 171, 205-209.	1.2	83
27	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 940-948.	1.5	78
28	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. <i>Journal of Clinical Investigation</i> , 2019, 130, 673-685.	3.9	78
29	Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. <i>Journal of Clinical Oncology</i> , 2014, 32, 2365-2372.	0.8	77
30	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 235-246.	2.0	76
31	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. <i>Blood</i> , 2018, 132, 298-298.	0.6	73
32	Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. <i>Blood</i> , 2017, 129, 906-916.	0.6	56
33	Oral Vancomycin Prophylaxis Is Highly Effective in Preventing <i>Clostridium difficile</i> Infection in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 68, 2003-2009.	2.9	54
34	Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1758-1766.	2.0	52
35	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. <i>Journal of Clinical Oncology</i> , 2015, 33, 2392-2398.	0.8	52
36	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	52

#	ARTICLE	IF	CITATIONS
37	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49
38	Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor α^c T-cell therapy in B-cell non-Hodgkin lymphomas. <i>Cytotherapy</i> , 2018, 20, 1415-1418.	0.3	45
39	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	45
40	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. <i>Blood</i> , 2015, 126, 478-485.	0.6	37
41	$\langle \text{CAR} \rangle \langle \text{T} \rangle$ cells merge into the fast lane of cancer care. <i>American Journal of Hematology</i> , 2016, 91, 146-150.	2.0	36
42	Donor leukocyte infusions in myeloid malignancies: new strategies. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 737-755.	0.7	34
43	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. <i>Bone Marrow Transplantation</i> , 2019, 54, 212-217.	1.3	34
44	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1961-1967.	2.0	30
45	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016, 128, 974-974.	0.6	28
46	Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. <i>American Journal of Hematology</i> , 2016, 91, 672-676.	2.0	27
47	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 515-521.	2.0	24
48	Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T cell therapy for chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2019, 94, S10-S17.	2.0	22
49	Nelarabine, cyclophosphamide and etoposide for adults with relapsed T cell acute lymphoblastic leukaemia and lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 332-334.	1.2	21
50	Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case report. <i>American Journal of Transplantation</i> , 2018, 18, 745-749.	2.6	20
51	Risk of invasive fungal infections in patients with $\langle \text{high} \rangle$ risk MDS and $\langle \text{AML} \rangle$ receiving hypomethylating agents. <i>American Journal of Hematology</i> , 2020, 95, 792-798.	2.0	20
52	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 57-57.	0.6	18
53	The promise of chimeric antigen receptor T cells ($\langle \text{CART} \rangle$ s) in leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 13-26.	1.2	17
54	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	0.6	16

#	ARTICLE	IF	CITATIONS
55	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 279-288.	1.0	15
56	A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy. <i>Blood</i> , 2019, 134, 4108-4108.	0.6	14
57	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. <i>Blood</i> , 2014, 124, 380-380.	0.6	14
58	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	1.2	11
59	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
60	Novel approaches to allogeneic stem cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 3-15.	1.4	10
61	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. <i>Blood</i> , 2012, 120, 717-717.	0.6	10
62	R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 92-97.	0.2	9
63	A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia. <i>Blood</i> , 2014, 124, 3758-3758.	0.6	9
64	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. <i>American Journal of Hematology</i> , 2016, 91, 453-460.	2.0	7
65	Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. <i>Blood Advances</i> , 2018, 2, 575-585.	2.5	7
66	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitidine for Initial Therapy in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 795-795.	0.6	7
67	Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 594-599.	2.0	6
68	Cellular Adoptive Immunotherapy After Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. <i>Cancer Treatment and Research</i> , 2009, 144, 497-537.	0.2	5
69	Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2078-2083.	1.3	4
70	Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 18.e1-18.e1.	0.6	4
71	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. <i>Blood</i> , 2020, 136, 30-32.	0.6	4
72	Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models. <i>Blood</i> , 2017, 130, 807-807.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2016, 91, 883-887.	2.0	3
74	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CART T Cell Efficacy. <i>Blood</i> , 2018, 132, 235-235.	0.6	2
75	Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells. <i>Blood</i> , 2021, 138, 166-166.	0.6	2
76	Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Future Oncology</i> , 2022, 18, 2415-2431.	1.1	2
77	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1203-1208.	2.0	1
78	Immunotherapy with cells (article not eligible for CME credit). <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 590-597.	0.9	1
79	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 431.e1-431.e8.	0.6	1
80	Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing. <i>Blood</i> , 2018, 132, 2134-2134.	0.6	1
81	Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients. <i>Blood</i> , 2021, 138, 2888-2888.	0.6	1
82	Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
83	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. <i>Blood</i> , 2008, 112, 4033-4033.	0.6	0
84	Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).. <i>Blood</i> , 2010, 116, 4574-4574.	0.6	0
85	Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210807.	0.5	0